Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Operations: 2017-2024

Historic Cash from Operations for IDEAYA Biosciences (IDYA) over the last 8 years, with Dec 2024 value amounting to -$247.6 million.

  • IDEAYA Biosciences' Cash from Operations rose 388.85% to $142.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.3 million, marking a year-over-year increase of 31.68%. This contributed to the annual value of -$247.6 million for FY2024, which is 114.87% down from last year.
  • Per IDEAYA Biosciences' latest filing, its Cash from Operations stood at -$247.6 million for FY2024, which was down 114.87% from -$115.2 million recorded in FY2023.
  • IDEAYA Biosciences' 5-year Cash from Operations high stood at $55.5 million for FY2020, and its period low was -$247.6 million during FY2024.
  • For the 3-year period, IDEAYA Biosciences' Cash from Operations averaged around -$150.0 million, with its median value being -$115.2 million (2023).
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 241.08% in 2020, then slumped by 200.57% in 2021.
  • Over the past 5 years, IDEAYA Biosciences' Cash from Operations (Yearly) stood at $55.5 million in 2020, then tumbled by 200.57% to -$55.8 million in 2021, then crashed by 56.29% to -$87.2 million in 2022, then plummeted by 32.18% to -$115.2 million in 2023, then plummeted by 114.87% to -$247.6 million in 2024.